样式: 排序: IF: - GO 导出 标记为已读
-
PORT: A Randomized, Cross-over, Phase 2 Study of Melflufen Peripheral versus Central Intravenous Administration in Patients with Relapsed/Refractory Multiple Myeloma Clin. Lymph. Myelom Leuk. (IF 2.7) Pub Date : 2024-02-23 Ludek Pour, Ilina Micheva, Ganna Usenko, Gabor Mikala, Tamas Masszi, Kameliya Simeonova, Marcus Thuresson, Gunilla Huledal, Stefan Norin, Nicolaas A. Bakker, Jiri Minarik
Melflufen, a first-in-class alkylating peptide-drug conjugate, rapidly enters tumor cells and metabolizes to melphalan. In previous studies, melflufen was administered via central venous catheter (CVC). However, administration by peripheral venous catheter (PVC) may be preferable. PORT was a two-period, phase 2 crossover study of CVC versus PVC melflufen administration in patients with relapsed/refractory
-
Financial toxicity, time toxicity, and quality of life in multiple myeloma Clin. Lymph. Myelom Leuk. (IF 2.7) Pub Date : 2024-02-23 Rahul Banerjee, Andrew J. Cowan, Marivel Ortega, Constance Missimer, Paul A. Carpenter, Masumi Ueda Oshima, Rachel B. Salit, Phuong T. Vo, Catherine J. Lee, Rohtesh S. Mehta, Nicole M. Kuderer, Veena Shankaran, Stephanie J. Lee, Christopher T. Su
Patients with multiple myeloma (MM) may be on therapy for years, which can lead to financial toxicity (FinTox) or time toxicity (TimeTox). The prevalence, predictors, and quality of life (QOL) impacts of FinTox and TimeTox during different phases of MM treatment have not been characterized. We conducted a single-center cross-sectional survey of patients with MM who had undergone transplantation. FinTox+
-
SOHO State of the Art Updates and Next Questions: Treatment Evolution of Mantle Cell Lymphoma: Navigating the Different Entities and Biological Heterogeneity of Mantle Cell Lymphoma in 2024 Clin. Lymph. Myelom Leuk. (IF 2.7) Pub Date : 2024-02-22 Andrew Ip, Alexandra Della Pia, Andre Goy
Progress in mantle cell lymphoma (MCL) has led to significant improvement in outcomes of patients even in the real world (RW) setting albeit to a lesser degree. In parallel to the demonstration of benefit using combination therapy with rituximab plus high-dose cytarabine (R-AraC) as well as dose intensive therapy-autologous stem cell transplantation (DIT-ASCT) consolidation and maintenance, it became
-
Dampening Logistics Creating Inequitable Access- A Major Threat Despite Advancements Clin. Lymph. Myelom Leuk. (IF 2.7) Pub Date : 2024-02-22 Fathima Shehnaz Ayoobkhan, Al- Ola Abdallah, Faiz Anwer, Nausheen Ahmed
-
SOHO State of the Art Updates & Next Questions | Measurable Residual Disease in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Clin. Lymph. Myelom Leuk. (IF 2.7) Pub Date : 2024-02-21 Nicholas J. Short, Elias Jabbour, Hagop Kantarjian
Assessment of measurable residual disease (MRD) provides important prognostic information and can inform decision-making about appropriate consolidative therapy in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). Many contemporary treatment protocols for Ph+ ALL achieve high rates of MRD negativity, and several analyses suggest that allogeneic hematopoietic stem
-
Comparison of the efficacy among nilotinib, dasatinib, flumatinib and imatinib in newly diagnosed chronic-phase chronic myeloid leukemia patients: A real-world multi-center retrospective study Clin. Lymph. Myelom Leuk. (IF 2.7) Pub Date : 2024-02-15 Xiaoshuai Zhang, Na Xu, Yunfan Yang, Hai Lin, Bingcheng Liu, Xin Du, Xiaoli Liu, Rong Liang, Chunyan Chen, Jian Huang, Huanling Zhu, Ling Pan, Xiaodong Wang, Guohui Li, Zhuogang Liu, Yanqing Zhang, Zhenfang Liu, Jianda Hu, Chunshui Liu, Fei Li, Wei Yang, Li Meng, Yanqiu Han, Li'e Lin, Zhenyu Zhao, Chuanqing Tu, Caifeng Zheng, Yanliang Bai, Zeping Zhou, Suning Chen, Huiying Qiu, Lijie Yang, Xiuli Sun
There are limited data comprehensively comparing therapy responses and outcomes among nilotinib, dasatinib, flumatinib and imatinib for newly diagnosed chronic-phase chronic myeloid leukemia in a real-world setting. Data from patients with chronic-phase CML receiving initial a second-generation tyrosine-kinase inhibitor (2G-TKI, nilotinib, dasatinib or flumatinib) or imatinib therapy from 77 Chinese
-
Safety and Toxicity Profiles of CAR T Cell Therapy in Non-Hodgkin Lymphoma: A Systematic Review and Meta-Analysis Clin. Lymph. Myelom Leuk. (IF 2.7) Pub Date : 2024-02-15 Samuel Yamshon, Caitlin Gribbin, Mohammad Alhomoud, Nora Chokr, Zhengming Chen, Michelle Demetres, Michelle Pasciolla, John Leonard, Tsiporah Shore, Peter Martin
The application of CD19-directed chimeric antigen receptor T (CAR T) cell therapy has improved outcomes for thousands of patients with non-Hodgkin B cell lymphoma (NHL). The toxicities associated with various CAR T cell products, however, can be severe and difficult to anticipate. In this systematic review and meta-analysis, we set out to determine whether there are measurable differences in common
-
Alternative Dosing Schedules of Azacitidine: a real-world study across South American centers Clin. Lymph. Myelom Leuk. (IF 2.7) Pub Date : 2024-02-14 Lucas Castelo, Wellington Fernandes da Silva, Marco Lincango, Valeria Buccheri, Agustina Perusini, Jorge Arbelbide, Marcelo Iastrebner, Jacqueline Gonzalez, Patricio Pereyra, Thales Dalessandro M. Pereira, Luan Lima Marchi, Vanderson Rocha, Carolina B. Belli, Elvira Deolinda Rodrigues Pereira Velloso
-
Treatment Pattern, Healthcare Resource Utilization and Symptom Burden Among Patients with Triple Class Exposed Multiple Myeloma: A Population-Based Cohort Study Clin. Lymph. Myelom Leuk. (IF 2.7) Pub Date : 2024-02-14 Hira Mian, Hsien Seow, Gregory R. Pond, Anastasia Gayowsky, Ronan Foley, Amaris Balistky, Mohammed Ebraheem, Christopher Cipkar, Hyra Sapru, Ghulam Rehman Mohyuddin, Samer Al Hadidi, Alissa Visram
This study aims to describe the treatment patterns, outcomes, health care utilization and symptom burden of triple class exposed (TCE) relapsed/refractory patents with multiple myeloma (MM) receiving a subsequent line of treatment (LOT). This is a retrospective observational cohort study using administrative databases in Ontario, Canada. Outcomes were captured for TCE patients receiving a subsequent
-
Long-term follow up of the combination of ofatumumab, high-dose methylprednisolone, and lenalidomide for untreated chronic lymphocytic leukemia with biomarker analysis Clin. Lymph. Myelom Leuk. (IF 2.7) Pub Date : 2024-02-13 Julio C Chavez, Ariel Grajales, Jose Sandoval-Sus, Elyce Turba, Lisa Nodzon, Angimar Uriepero, Mohammad Ammad-Ud-Din, Eva Sahakian, Rami Komrokji, Lubomir Sokol, Frederick L Locke, Bijal Shah, Jeffrey Lancet, Eduardo M Sotomayor, Mohamed A. Kharfan-Dabaja, Celeste Bello, Javier Pinilla-Ibarz
Advancements in frontline therapy and chemotherapy-sparing treatments in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) have altered the treatment algorithms of this disease. We present a frontline alternative for treatment- naïve (TN) CLL/SLL patients. This was a single-center, phase 2 study of high-dose methylprednisolone (HDMP) and ofatumumab with lenalidomide and ofatumumab consolidative
-
Recent Developments in Convenience of Administration of the Anti-CD38 Antibody Isatuximab: Subcutaneous Delivery and Fast Intravenous Infusion in Patients With Multiple Myeloma Clin. Lymph. Myelom Leuk. (IF 2.7) Pub Date : 2024-02-12 Hang Quach, Gurdeep Parmar, Maria-Victoria Mateos, Sikander Ailawadhi, Xavier Leleu
Isatuximab-based combinations are among the accepted standard-of-care regimens for early-line treatment of patients with relapsed/refractory multiple myeloma (RRMM), based on the results of the Phase 3 ICARIA-MM and IKEMA trials. Further study findings have shown benefit with Isa-based combinations in patients with newly diagnosed MM, as reported from the randomized GMMG-HD7 and CONCEPT trials. Isa
-
Hypomethylating agents and venetoclax for acute myeloid leukemia relapsed after hematopoietic stem cell transplant Clin. Lymph. Myelom Leuk. (IF 2.7) Pub Date : 2024-02-12 Filip Ionescu, Jerel C David, Apoorva Ravichandran, David A Sallman, Kendra Sweet, Rami S Komrokji, Onyee Chan, Andrew Kuykendall, Eric Padron, Rawan Faramand, Nelli Bejanyan, Farhad Khimani, Hany Elmariah, Joseph Pidala, Asmita Mishra, Lia Perez, Taiga Nishihori, Jeffrey E Lancet
Hypomethylating agent + venetoclax is an effective frontline combination for acute myeloid leukemia, but its efficacy and safety in post-allogeneic hematopoietic cell transplant (alloHCT) relapse remain underexplored. Outcomes have been poor for this population, with no standard treatment. We retrospectively analyzed 72 Ven-naïve patients who received hypomethylating agents + venetoclax at relapse
-
Real-world Survival, Healthcare Resource Utilization, and Costs among U.S. Elderly Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Treated with R-GemOx in the Relapsed/Refractory Setting Clin. Lymph. Myelom Leuk. (IF 2.7) Pub Date : 2024-02-09 Mahek Garg, Justin Puckett, Sachin Kamal-Bahl, Monika Raut, Katherine Elizabeth Ryland, Jalpa A. Doshi, Scott F. Huntington
Little recent real-world evidence exists on overall survival, healthcare resource utilization (HCRU), and costs among R/R DLBCL patients treated with the combination of rituximab, gemcitabine, and oxaliplatin (R-GemOx), a widely-used regimen for patients ineligible for stem cell transplant due to age or comorbidities. This retrospective analysis used 2014-2019 U.S. Medicare claims. Individuals aged
-
Efficacy and safety of children with relapsed/refractory B-cell acute lymphoblastic leukemia after anti-CD19 CAR T-cell therapy without bridging transplantation Clin. Lymph. Myelom Leuk. (IF 2.7) Pub Date : 2024-02-07 Qianwen Shang, Lian Xue, Aidong Lu, Yueping Jia, YingXi Zuo, Huimin Zeng, Leping Zhang
Anti-CD19 chimeric antigen receptor (CAR) T-cell therapies have demonstrated significant efficacy in achieving complete remission (CR) in pediatric patients with relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL). However, a considerable number of patients experience relapse within one year after CAR T-cell therapy, leading to an extremely poor prognosis, particularly in patients
-
Azacitidine Post-transplant Maintenance Improves Disease Progression in High-Risk Acute Myeloid Leukemia and Myelodysplastic Syndrome Clin. Lymph. Myelom Leuk. (IF 2.7) Pub Date : 2024-02-03 Oren Pasvolsky, Rima M. Saliba, Uday R. Popat, Amin Alousi, Rohtesh Mehta, Jason Yeh, Gheath Al-Atrash, Masood Adeel, Jeremy Ramdial, David Marin, Gabriela Rondon, Partow Kebriaei, Richard Champlin, Naval Daver, Courtney Dinardo, Nicholas J. Short, Elizabeth J. Shpall, Betül Oran
Outcomes of 93 adult patients with FLT3-negative AML/MDS who received post-alloHCT AZA maintenance were compared to 357 patients who received no maintenance. Three-year incidence of progression was 29% versus 33% in the AZA and control groups, respectively (09). A protective effect of AZA on progression was observed in high-risk AML/MDS (HR = 0.4, 95% CI = 0.2-0.8, 009).
-
Outcome of Patients with Relapsed Acute Promyelocytic Leukemia Clin. Lymph. Myelom Leuk. (IF 2.7) Pub Date : 2024-02-03 Koji Sasaki, Farhad Ravandi, Tapan Kadia, Courtney D DiNardo, Musa Yilmaz, Nicholas Short, Elias Jabbour, Keyur P Patel, Sanam Loghavi, Sherry Pierce, Gautam Borthakur, Hagop Kantarjian
The outcome of patients with acute promyelocytic leukemia (APL) has improved significantly since the introduction of all-trans retinoic acid (ATRA) and arsenic trioxide (ATO) as APL therapies. The optimal therapy for APL relapse is believed to require autologous or allogeneic stem cell transplantation (SCT) based on historical experience. To evaluate the outcome of patients with relapsed APL before
-
-
Healthcare resource utilization and cost-of-illness in systemic light chain (AL) amyloidosis in Europe: results from the real-world, retrospective EMN23 study Clin. Lymph. Myelom Leuk. (IF 2.7) Pub Date : 2024-02-01 Arnaud Jaccard, Frank Bridoux, Wilfried Roeloffzen, Monique C. Minnema, Rui Bergantim, Roman Hájek, Cristina João, M. Teresa Cibeira, Giovanni Palladini, Stefan Schönland, Giampaolo Merlini, Paolo Milani, Meletios A. Dimopoulos, Sriram Ravichandran, Ute Hegenbart, Hermine Agis, Blanca Gros, Aisha Asra, Valeria Magarotto, Giorgos Cheliotis, Giorgos Psarros, Pieter Sonneveld, Ashutosh Wechalekar, Efstathios
To report healthcare resource utilization (HCRU) and safety outcomes in systemic light chain (AL) amyloidosis from the EMN23 study. The retrospective, observational, multinational EMN23 study included 4,480 patients initiating first-line treatment for AL amyloidosis in 2004–2018 and assessed, among other objectives, HCRU and safety outcomes. HCRU included hospitalizations, examinations, and dialysis;
-
Optimizing the CAR T-Cell Therapy Experience in Multiple Myeloma: Clinical Pearls From an Expert Roundtable Clin. Lymph. Myelom Leuk. (IF 2.7) Pub Date : 2024-02-01 Sikander Ailawadhi, Leyla Shune, Sandy W. Wong, Yi Lin, Krina Patel, Sundar Jagannath
Chimeric antigen receptor T-cell (CAR-T) therapies offer substantial advancement in the treatment of multiple myeloma (MM). However, the CAR-T therapy process involves complex decision-making that is informed by many variables. This review aims to provide an overview of the patient selection and administration process for CAR-T therapy for MM from the perspective of experienced healthcare providers
-
-
THE ITALIAN MULTICENTRIC RANDOMIZED OPTKIMA TRIAL ON FIXED VS PROGRESSIVE INTERMITTENT TKI THERAPY IN CML ELDERLY PATIENTS: 3-YEARS OF MOLECULAR RESPONSE AND QUALITY OF LIFE MONITORING AFTER COMPLETING THE TREATMENT PLAN. Clin. Lymph. Myelom Leuk. (IF 2.7) Pub Date : 2024-01-25 M. Malagola, A. Iurlo, C. Bucelli, E. Abruzzese, M. Bonifacio, F. Stagno, G. Binotto, M. D'Adda, M. Lunghi, M. Crugnola, M.L. Ferrari, F. Lunghi, F. Castagnetti, G. Rosti, R. M Lemoli, R. Sancetta, M.R. Coppi, M.T. Corsetti, M De Gobbi, A. Romano, D. M Russo
Background Intermittent treatment with TKIs is an option for elderly CML patients who are often candidate to life-long treatment. Matherials and Methods The Italian phase III multicentric randomized OPTkIMA study aimed to evaluate if a progressive de-escalation of TKIs is able to maintain the MR3.0 and to improve Health Related Quality of Life (HRQoL) in CML elderly patients. Results 215 patients in
-
A comparison of 3-year follow-up of ZUMA-5 (axicabtagene ciloleucel) with SCHOLAR-5 in relapsed/refractory follicular lymphoma Clin. Lymph. Myelom Leuk. (IF 2.7) Pub Date : 2024-01-24 Paola Ghione, M Lia Palomba, Markqayne D Ray, Eve Limbrick-Oldfield, Jessica Owen, Steve Kanters, Sabela Bobillo, Maria Teresa Ribiero, Caron A Jacobson, Sattva S Neelapu, Herve Ghesquieres, Myrna Nahas, Sara Beygi, Anik R Patel, John G Gribben
In the pivotal ZUMA-5 trial, axicabtagene ciloleucel (axi-cel; an autologous anti-CD19 chimeric antigen receptor T-cell therapy) demonstrated high rates of durable response in relapsed/refractory follicular lymphoma patients. SCHOLAR-5 is an external control cohort designed to act as a comparator to ZUMA-5. Here, we present an updated comparative analysis of ZUMA-5 and SCHOLAR-5, using the 36-month
-
SOHO State of the Art Updates and Next Questions | Diagnosis, Outcomes, and Management of Prefibrotic Myelofibrosis Clin. Lymph. Myelom Leuk. (IF 2.7) Pub Date : 2024-01-21 Pankit Vachhani, Sanam Loghavi, Prithviraj Bose
Prefibrotic primary myelofibrosis (prefibrotic PMF) is a myeloproliferative neoplasm with distinct characteristics comprising histopathological and clinico-biological parameters. It is classified as a subtype of primary myelofibrosis. In clinical practice, it is essential to correctly distinguish prefibrotic PMF from essential thrombocythemia especially but also overt PMF besides other myeloid neoplasms
-
SOHO State of the Art Updates and Next Questions | Will CAR-T Replace ASCT in NDMM? Clin. Lymph. Myelom Leuk. (IF 2.7) Pub Date : 2024-01-19 Eric Jurgens, Saad Z. Usmani
The treatment landscape for multiple myeloma (MM) has rapidly evolved over the last two decades. The development of triplet and quadruplet regimens including proteasome inhibitors (PI), immunomodulatory agents (IMiDs), and anti-CD38 monoclonal antibodies has dramatically extended overall survival. In addition to effective multidrug regimens, autologous stem cell transplant (ASCT) is a cornerstone of
-
Venetoclax and Cobimetinib in Relapsed/Refractory AML: A Phase 1b Trial Clin. Lymph. Myelom Leuk. (IF 2.7) Pub Date : 2024-01-18 Marina Y. Konopleva, Monique Dail, Naval G. Daver, Jacqueline S. Garcia, Brian A. Jonas, Karen W.L. Yee, Kevin R. Kelly, Norbert Vey, Sarit Assouline, Gail J. Roboz, Stefania Paolini, Daniel A. Pollyea, Agostino Tafuri, Joseph M. Brandwein, Arnaud Pigneux, Bayard L. Powell, Pierre Fenaux, Rebecca L. Olin, Giuseppe Visani, Giovanni Martinelli, Michael Andreeff
Background Therapies for relapsed/refractory (R/R) acute myeloid leukemia (AML) remain limited and outcomes poor, especially amongst patients who are ineligible for cytotoxic chemotherapy or targeted therapies. Patients and Methods This phase 1b trial evaluated venetoclax, a B-cell lymphoma-2 (BCL-2) inhibitor, plus cobimetinib, a MEK1/2 inhibitor, in patients with R/R AML, ineligible for cytotoxic
-
Serologic Response to Vaccine for COVID-19 in Patients with Hematologic Malignancy: A Prospective Cohort Study Clin. Lymph. Myelom Leuk. (IF 2.7) Pub Date : 2024-01-18 Alexandra Hillyer, Anthony Quint, Artin Ghassemian, Nicolette Joh-Carnella, Michael J. Knauer, Danny Dawd, Alejandro Lazo-Langner, Joy Mangel, Selay Lam, Husam Abdoh, Anargyros Xenocostas, Uday Deotare, Lalit Saini, Cheryl Foster, Martha Louzada, Jenny Ho, Ian Chin Yee, Chai W. Phua
Background Patients with hematological cancers have increased COVID-19 morbidity and mortality, and these patients show attenuated vaccine responses. This study aimed to characterize the longitudinal humoral immune responses to COVID-19 vaccination in patients with hematological malignancies. Patients and methods We conducted a prospective cohort study, collecting samples from March 2021–July 2022
-
Geographic and Racial Disparities in Chimeric Antigen Receptor–T Cells and Bi-specific Antibodies Trials Access for Diffuse Large B-Cell Lymphoma Clin. Lymph. Myelom Leuk. (IF 2.7) Pub Date : 2024-01-17 Moazzam Shahzad, Muhammad Fareed Khalid, Muhammad Kashif Amin, Ahmad Basharat, Mohammad Ammad-Ud-Din, Robin Park, Iqra Anwar, Muhammad Salman Faisal, Michael Jaglal
We investigate the geographical and racial disparities in accessing CAR-T and bispecific antibodies trials for DLBCL. ClinicalTrials.gov was searched, and 75 trials with at least one open site in the US were included. 2020 US Census Bureau data was used to obtain data on race and ethnicity. SPSS version 26 was used for analysis. There were 62 CAR-T and 13 bispecific antibodies trials with 6221 enrolled
-
Prognostic Impact of Bone Marrow Fibrosis And Effects of Tyrosine Kinase Inhibitors on Bone Marrow Fibrosis in Chronic Myeloid Leukemia Clin. Lymph. Myelom Leuk. (IF 2.7) Pub Date : 2024-01-17 Mehmet Sezgin Pepeler, Mesut Tıglıoglu, Simten Dagdas, Esra Ozhamacıoglu, Unsal Han, Aynur Albayrak, Mürüvvet Seda Aydın, Gülten Korkmaz, Merve Pamukcuoğlu, Funda Ceran, Murat Albayrak, Gülsüm Ozet
Background and Aim Myelofibrosis is reported in around 40% of newly diagnosed chronic myeloid leukemia (CML) patients and have an important role in the pathobiology and prognosis of CML. This retrospective study aimed to evaluate the effects of bone marrow (BM) fibrosis on disease prognosis and the effects of specific tyrosine-kinase inhibitors (TKIs) on BM fibrosis in CML patients. Methods The study
-
Chimeric Antigen Receptor T - Cell Therapy for Large B-Cell Lymphoma Patients with Central Nervous System Involvement, a Systematic Review and Meta-analysis Clin. Lymph. Myelom Leuk. (IF 2.7) Pub Date : 2024-01-12 Ghada Elgohary, Yang Yang, Mia Gergis, Dongni Yi, Usama Gergis
Chimeric Antigen Receptor T-cell (CAR T-cell) therapy is an effective treatment for relapsed/refractory (R/R) large B cell lymphoma (LBCL). However, patients with central nervous system (CNS) lymphoma were excluded in most of the CAR T-cell therapy trials. This meta-analysis assesses the efficacy with CAR T-cell therapy in LBCL patients with CNS involvement. Two reviewers independently searched PubMed
-
A review of the therapeutic role of bosutinib in chronic myeloid leukemia Clin. Lymph. Myelom Leuk. (IF 2.7) Pub Date : 2024-01-12 H.M. Kantarjian, E.J. Jabbour, J.H. Lipton, F. Castagnetti, T.H. Brümmendorf
Background The development of the BCR::ABL1 tyrosine kinase inhibitors (TKIs) has transformed Philadelphia chromosome (Ph)–positive chronic myeloid leukemia (CML) from a fatal disease to an often-indolent illness that, when managed effectively, can restore a life expectancy close to that of the normal population. Bosutinib is a second-generation TKI approved for adults with Ph-positive CML in chronic
-
SOHO State of the Art Updates and Next Questions ࣦ CTLs for Infections Following Stem Cell Transplantation Clin. Lymph. Myelom Leuk. (IF 2.7) Pub Date : 2024-01-09 Ariel Rischall, Amanda Olson
Allogeneic hematopoietic stem cell transplantation (AHSCT) is an important modality in the treatment of acute leukemia and other hematologic disorders. The post-transplant period is associated with prolonged periods of impaired immune function. Delayed T-cell immune reconstitution is correlated with increased risk of viral, bacterial, and fungal infections. This risk increases with high intensity inductions
-
-
-
SOHO State of the Art Updates and Next Questions | Next Questions: Acute Lymphoblastic Leukemia Clin. Lymph. Myelom Leuk. (IF 2.7) Pub Date : 2024-01-08 Jayastu Senapati, Hagop Kantarjian, Fadi G. Haddad, Nicholas J. Short, Mary Alma Welch, Nitin Jain, Elias Jabbour
The integration of immune and targeted therapies into the treatment of acute lymphoblastic leukemia (ALL) has significantly improved outcomes, reduced the intensity and duration of chemotherapy, and the reliance on allogeneic stem cell transplantation (SCT). In younger patients with Philadelphia chromosome (Ph)-negative ALL, treatment with Hyper-CVAD and blinatumomab +/- inotuzumab has improved the
-
An Open-Label Phase 1 Study of Metformin and Nelfinavir in Combination with Bortezomib in Patients with Relapsed and Refractory Multiple Myeloma Clin. Lymph. Myelom Leuk. (IF 2.7) Pub Date : 2024-01-06 Ibrahim Alodhaibi, Sikander Ailawadhi, Gabriel Perez Burbano, Patrick J. O'Brien, Francis K. Buadi, Suzanne Hayman, Shaji K. Kumar, Wilson I. Gonsalves
Background In preclinical models, combining a GLUT4 inhibitor with an oxidative phosphorylation inhibitor shows synergistic therapeutic potential against multiple myeloma (MM). Thus, this study evaluated the safety and tolerability of repurposing metformin, a complex I inhibitor, and nelfinavir, a GLUT4 inhibitor, in combination with bortezomib for the treatment of relapsed/refractory MM that had progressed
-
Corrigendum to “AML-068 - Survival Differences in Patients With Acute Myeloid Leukemia (AML) Treated With Oral Azacitidine (Oral-AZA) as Maintenance and Those Eligible but Not Treated in a US Electronic Health Record (EHR) Database” [Clinical Lymphoma, Myeloma & Leukemia, 23S1 (2023) S1-S593] Clin. Lymph. Myelom Leuk. (IF 2.7) Pub Date : 2024-01-04 Alice Mims, Zhuoer Xie, Alberto Vasconcelos, Maria Strocchia, Willem Heydendael, Manoj Chevli, David Rotter, Ravi Potluri, Thomas Prebet, Jan Sieluk
Abstract not available
-
Racial disparities in Mycosis Fungoides/Sézary Syndrome – A Single-center observational study of 292 patients. Clin. Lymph. Myelom Leuk. (IF 2.7) Pub Date : 2024-01-03 Ashley R. Gandham, Shamir Geller, Stephen W. Dusza, Thomas S. Kupper, Patricia. L. Myskowski
Background Clinical presentation of Mycosis fungoides/Sézary syndrome (MF/SS) in Black and African American (AA) patients can be heterogenous with poor survival reported in AA/black patients. In this study, we aim to characterize differences between AA/black and white patients with MF/SS. Patients and Methods A retrospective single-center hospital-based case-control study including 292 MF/SS patients
-
Dose-Dense Mini-Hyper-CVD, Inotuzumab Ozogamicin and Blinatumomab Achieves Rapid MRD-Negativity in Philadelphia Chromosome-Negative B-cell Acute Lymphoblastic Leukemia: Dose-dense mini-Hyper-CVD, inotuzumab ozogamicin and blinatumomab Clin. Lymph. Myelom Leuk. (IF 2.7) Pub Date : 2023-12-30 Nicholas J. Short, Elias Jabbour, Trevor Jamison, Shilpa Paul, Branko Cuglievan, David McCall, Amber Gibson, Nitin Jain, Fadi G. Haddad, Lewis F. Nasr, Kayleigh R. Marx, Caitlin Rausch, Jonathan M. Savoy, Rebecca Garris, Farhad Ravandi, Hagop Kantarjian
Background The combination of low-intensity chemotherapy and inotuzumab ozogamicin (INO), with sequential blinatumomab, is highly effective in older adults with newly diagnosed B-cell acute lymphoblastic leukemia (ALL) and in relapsed or refractory B-cell ALL. Earlier, “dose-dense” administration of blinatumomab could lead to earlier and deeper measurable residual disease (MRD) responses and better
-
Second Treatment-Free Remission Attempt in Patients with Chronic Myeloid Leukemia Clin. Lymph. Myelom Leuk. (IF 2.7) Pub Date : 2023-12-29 Hiroshi Ureshino, Kazuharu Kamachi, Shinya Kimura
Long-term survival outcomes of patients with chronic myeloid leukemia in the chronic phase (CML-CP) are now similar to those of the general population, following the introduction of ABL1 tyrosine kinase inhibitors (TKIs). Approximately 40–80% of patients with CML successfully achieved treatment-free remission after the first attempt of TKI discontinuation (TFR1), after achieving a durable deep molecular
-
Effect of Tyrosine Kinase Inhibitor Therapy on Estimated Glomerular Filtration Rate in Patients with Chronic Myeloid Leukemia Clin. Lymph. Myelom Leuk. (IF 2.7) Pub Date : 2023-12-28 Özge Sönmez, Nurgül Özgür Yurttaş, İlker İhtiyaroğlu, HalilMete Çakır, Zeynep Atlı, Tuğrul Elverdi, Ayşe Salihoğlu, Nurhan Seyahi, Muhlis Cem Ar, Şeniz Öngören, Zafer Başlar, Teoman Soysal, Ahmet Emre Eşkazan
Introduction The advent of tyrosine kinase inhibitors (TKIs) was revolutionary in the management of chronic myeloid leukemia (CML). Although TKIs were generally considered to be safe, they can be associated with renal injury. We evaluated the effect of TKIs on renal functions in a cohort of patients with long-term follow-up. Material and Methods We retrospectively examined patients with chronic phase
-
Epidemiologic characteristics, treatment patterns, and survival analysis of Plasmablastic Lymphoma in the US: A SEER and NCDB analysis. Clin. Lymph. Myelom Leuk. (IF 2.7) Pub Date : 2023-12-25 Alec R. Hansen, Victoria A. Vardell, Lindsey A. Fitzgerald
-
Recent Advances in the Biology and CD123-Directed Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm: Tagraxofusp, a CD123-directed therapy, in BPDCN Clin. Lymph. Myelom Leuk. (IF 2.7) Pub Date : 2023-12-20 Naveen Pemmaraju, Eric Deconinck, Priyanka Mehta, Irwin Walker, Marco Herling, Francine Garnache-Ottou, Nadia Gabarin, Clinton J.V. Campbell, Johannes Duell, Yakir Moshe, Tariq Mughal, Mohamad Mohty, Emanuele Angelucci
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is an aggressive myeloid malignancy of the dendritic cell lineage that affects patients of all ages, though the incidence appears to be highest in patients over the age of 60 years. Diagnosis is based on the presence of plasmacytoid dendritic cell precursors expressing CD123, the interleukin-3 (IL-3) receptor alpha, and a distinct histologic appearance
-
Real-world Effectiveness of Azacitidine in Treatment-Naive Patients With Higher-risk Myelodysplastic Syndromes Clin. Lymph. Myelom Leuk. (IF 2.7) Pub Date : 2023-12-20 Nishanthan Rajakumaraswamy, Mitul Gandhi, Andrew H. Wei, David A. Sallman, Naval G. Daver, Shuyuan Mo, Shahed Iqbal, Roshan Karalliyadda, Manli Chen, Yunfei Wang, Paresh Vyas
-
Utilization of Autologous Hematopoietic Cell Transplantation Over Time in Multiple Myeloma: A Population-Based Study Clin. Lymph. Myelom Leuk. (IF 2.7) Pub Date : 2023-12-20 Naseem S. Esteghamat, Ann Brunson, Aaron S. Rosenberg, Sara J. Schonfeld, Bryan Valcarcel, Renata Abrahão, Julianne J.P. Cooley, Christa L. Meyer, Jeffery J. Auletta, Lindsay M. Morton, Lori Muffly, Ted Wun, Theresa H.M. Keegan
Purpose Autologous hematopoietic cell transplantation (autoHCT) is associated with survival benefits in multiple myeloma (MM), but utilization remains low and differs by sociodemographic factors. Prior population-based studies have not fully captured autoHCT utilization or examined relationships between sociodemographic factors and autoHCT trends over time. Patients and Methods We used a novel data
-
SOHO State of the Art Updates and Next Questions: Update on the Approach to Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Clin. Lymph. Myelom Leuk. (IF 2.7) Pub Date : 2023-12-14 Fadi G. Haddad, Elias Jabbour, Nicholas J. Short, Nitin Jain, Hagop Kantarjian
The outcome of Philadelphia chromosome (Ph)-positive acute lymphoblastic leukemia (ALL) has improved significantly following the introduction of the BCR::ABL1 tyrosine kinase inhibitors (TKIs). The addition of newer-generation and more potent TKIs resulted in higher rates of molecular responses and better survival. Achieving a complete molecular remission (CMR; disappearance of the BCR::ABL1 transcripts)
-
Multiple Myeloma: Validation of the Values and Preferences Elicitation Questionnaire- Cure and Survival Preference Scale (VPEQ-CSPS) Clin. Lymph. Myelom Leuk. (IF 2.7) Pub Date : 2023-12-14 Anastasiia Savchenko, Joseph D. Tariman, Alexandria Kohon, Shannon D. Simonovich, Thomas Dahan, Jessica Bishop-Royse
Background With the emergence of many novel therapies, the treatment decisions for multiple myeloma (MM) are increasingly guided by concerns of quality of life, achievement of cancer-free remission, living a longer overall survival, and a relentless search for a cure; however, the impact of various decision-making factors on patients’ actual therapy choices and the patients’ desire for cure and survival
-
SOHO State of the Art Updates and Next Questions || Chronic Myeloid Leukemia and Pregnancy: “Per Aspera Ad Astra” Clin. Lymph. Myelom Leuk. (IF 2.7) Pub Date : 2023-12-12 Elisabetta Abruzzese, Malgorzata Monika Trawinska, Paolo De Fabritiis, Simona Bernardi
Chronic myeloid leukemia (CML) has evolved from an invariably fatal disease to a chronic disorder that can be treated with targeted drugs and allows survival expectations approaching age-matched controls. Thus, pregnancy and conception in CML should not be precluded anymore; however, to ensure the well-being of both the mother and the developing fetus careful planning and management are required. Tyrosine
-
Mosunetuzumab Safety Profile in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma: Clinical Management Experience from a Pivotal Phase I/II Trial Clin. Lymph. Myelom Leuk. (IF 2.7) Pub Date : 2023-12-12 Matthew Matasar, Nancy L. Bartlett, Mazyar Shadman, Lihua E. Budde, Ian Flinn, Gareth P. Gregory, Won Seog Kim, Georg Hess, Dima El-Sharkawi, Catherine S. Diefenbach, Huang Huang, Iris To, Joana Parreira, Mei Wu, Antonia Kwan, Sarit Assouline
Background Mosunetuzumab is a CD20xCD3 T-cell engaging bispecific antibody approved in Europe and the United States for relapsed/refractory (R/R) follicular lymphoma (FL) after ≥2 prior therapies. Materials and Methods We present interim safety data from the mosunetuzumab GO29781 (NCT02500407) phase I/II dose-escalation study in R/R non-Hodgkin lymphoma (NHL), focusing on FL. Results Overall, 218 patients
-
Immunoglobulin high throughput sequencing (Ig-HTS) minimal residual disease (MRD) analysis is an effective surveillance tool in patients with mantle cell lymphoma Clin. Lymph. Myelom Leuk. (IF 2.7) Pub Date : 2023-12-10 Alexandra Rezazadeh, Julie Pruett, Amy Detzner, Natasha Edwin, Mehdi Hamadani, Nirav N. Shah, Timothy S. Fenske
Mantle cell lymphoma accounts for 4-6% of B-cell non-Hodgkin lymphoma (NHL) with historically poor outcomes. With the advent of intensive first-line, targeted, and cellular therapies, outcomes have improved, and initial remission can be 8-10 years or even longer. As patients experience longer remissions, this raises the question of the optimal surveillance modality. Peripheral blood minimal residual
-
Characterization and Outcomes of Spanish Patients With Relapsed/Refractory Multiple Myeloma Included in the LocoMMotion Study Clin. Lymph. Myelom Leuk. (IF 2.7) Pub Date : 2023-12-07 Maria-Victoria Mateos, Katja Weisel, Joris Diels, Alberto Arribas, Maria Tamayo, Jordan M. Schecter, Tito Roccia, Imène Haddad, Lida Pacaud, Philippe Moreau
Background Despite advances in treatments for multiple myeloma (MM), most patients relapse and become refractory to standard drug classes including immunomodulatory drugs (IMiDs), proteasome inhibitors (PIs), and anti-CD38 antibodies. The LocoMMotion study showed poor clinical outcomes in triple-class exposed patients with relapsed/refractory MM (RRMM) treated with real-world clinical practice (RWCP)
-
The prognostic significance of vitamin D deficiency in Korean patients with multiple myeloma Clin. Lymph. Myelom Leuk. (IF 2.7) Pub Date : 2023-12-06 Sejin Kim, Hyungwoo Cho, Miyoung Kim, Kyoungmin Lee, Shin Kim, Dok Hyun Yoon
Background Vitamin D deficiency is relatively common among patients with multiple myeloma. The prognostic significance of vitamin D deficiency in Asian patients with multiple myeloma remains unevaluated. This study aimed to assess the prognostic value of vitamin D levels in this Korean patient population. Methods From September 2017 to May 2020, 98 patients were enrolled in the study. Vitamin D deficiency
-
FOLINIC ACID OVER - RESCUE OF INTERMEDIATE DOSE METHOTREXATE Clin. Lymph. Myelom Leuk. (IF 2.7) Pub Date : 2023-12-05 Ian J Cohen
Abstract not available
-
SOHO State of the Art Updates and Next Questions | Oral Therapy in Acute Myeloid Leukemia Clin. Lymph. Myelom Leuk. (IF 2.7) Pub Date : 2023-12-01 Patrice Nasnas, Farhad Ravandi
With the recent development of several new effective agents, treatment of patients with acute myeloid leukemia (AML) is evolving. Molecularly targeted agents developed against leukemogenic pathways are demonstrating significant promise both as monotherapy and in combination with standard regimens. Although oral chemotherapeutic agents have long been used in the treatment of various malignancies, their
-
Predictors and impact of timing of disease progression following primary therapy in multiple myeloma: Running title: Progression after initial therapy of myeloma Clin. Lymph. Myelom Leuk. (IF 2.7) Pub Date : 2023-11-27 Sarah Goldman-Mazur, Alissa Visram, S. Vincent Rajkumar, Prashant Kapoor, Angela Dispenzieri, Martha Q. Lacy, Morie A. Gertz, Francis K. Buadi, Suzanne R. Hayman, David Dingli, Taxiarchis Kourelis, Wilson Gonsalves, Rahma Warsame, Eli Muchtar, Nelson Leung, Robert A. Kyle, Shaji K. Kumar
In multiple myeloma (MM) significant variation in progression-free survival (PFS) and overall survival (OS) is observed. We examined the outcomes of 1557 MM patients stratified into short (<2 years), medium (between 2-5 years) and long (>5 years) PFS. Short PFS occurred in 758 patients (48.7%), medium in 561 patients (36.2%), and long in 238 patients (15.3%). Median post-progression PFS was 9.2 months
-
Improvements in Patient-Reported Outcomes in Relapsed or Refractory Large B-Cell Lymphoma Patients Treated With Epcoritamab Clin. Lymph. Myelom Leuk. (IF 2.7) Pub Date : 2023-11-27 Tycel Phillips, Pieternella Lugtenburg, Anupama Kalsekar, Alex Mutebi, Anthony Wang, Julie Blaedel, Katherine Kosa, Susan Martin, Mariana Sacchi, Nurgul Kilavuz, Catherine Thieblemont
Background Patient-reported outcomes were evaluated in EPCORE NHL-1 in patients with relapsed or refractory (R/R) large B-cell lymphoma (LBCL) treated with epcoritamab monotherapy (NCT03625037). Materials and Methods Adults with R/R CD20+ LBCL and ≥2 prior systemic antilymphoma therapies, including anti-CD20, completed the Functional Assessment of Cancer Therapy–Lymphoma (FACT-Lym) and EQ-5D-3L. A
-
Multi-parametric flow cytometry in the evaluation of plasma cell proliferative disorders- Current paradigms for clinical practice Clin. Lymph. Myelom Leuk. (IF 2.7) Pub Date : 2023-11-27 Ritu Gupta, Dragan Jevremovic, Smith J. Mathew, Shaji Kumar
Diagnosis of plasma cell proliferative disorders (PCPDs) is primarily based on the demonstration of monoclonal protein (M-Protein) in blood and/ or urine which often precedes clinical manifestations of the disease. The basic pathophysiology behind the M-protein presence is the proliferation of clonal plasma cells (PCs) in bone marrow or extra-medullary sites and is assessed using cytomorphology and
-
SOHO State of the Art Update and Next Questions | Novel Therapies for Polycythemia Vera Clin. Lymph. Myelom Leuk. (IF 2.7) Pub Date : 2023-11-27 Lucia Masarova, Helen T. Chifotides
In the recent years, landmark advancements in the treatment of polycythemia vera (PV) have been achieved. We witnessed the regulatory approval of ropeginterferon and the advanced clinical development of other novel agents that may affect the underlying pathophysiological mechanisms of the disease. Agents with the potential of disease modification may soon overtake preceding treatment options that were
-
The Impact of Time from Diagnosis to Initiation of Chemotherapy on Survival of Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma in the Veterans Health Administration Clin. Lymph. Myelom Leuk. (IF 2.7) Pub Date : 2023-11-24 Gabriel Roman Souza, Zohra Nooruddin, Sophia Lee, Lauren Boyle, Kana Tai Lucero, Snegha Ananth, Kathleen Franklin, Michael Mader, Esteban Toro Velez, Amna Naqvi, Supreet Kaur
Introduction Our retrospective study evaluates the impact of time from diagnosis to treatment (TDT) on outcomes of patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL) treated within the Veterans Health Administration (VHA). Methods VHA patients diagnosed with DLBCL between 2011 and 2019 were included, those with primary central nervous system lymphoma were excluded. The median overall
-
Approach to Older Adults with Philadelphia-Chromosome Negative Acute Lymphoblastic Leukemia Clin. Lymph. Myelom Leuk. (IF 2.7) Pub Date : 2023-11-23 Shai Shimony, Marlise R. Luskin
Philadelphia-chromosome-negative (Ph-neg) acute lymphoblastic leukemia (ALL) has historically been associated with poor outcomes in older patients due to adverse disease biology, as well as inferior tolerance of conventional chemotherapy. Fortunately, novel therapies, including inotuzumab ozogamicin, blinatumomab, and venetoclax, are now being incorporated into first-line therapy to improve efficacy
-